Monte Rosa Therapeutics (GLUE) Total Liabilities (2020 - 2026)

Monte Rosa Therapeutics' Total Liabilities history runs 7 years deep, the most recent figure standing at $214.5 million for Q1 2026.

• On a quarterly basis, Total Liabilities rose 81.73% year-over-year to $214.5 million in Q1 2026; TTM through Mar 2026 was $214.5 million, a 81.73% increase from a year earlier, with the FY2025 full-year figure at $215.6 million, changed 0.09% from the prior year.
• Total Liabilities declined to $214.5 million in Q1 2026 per GLUE's latest filing, from $215.6 million in the prior quarter.
• Across five years, Total Liabilities topped out at $215.8 million in Q4 2024 and bottomed at $20.1 million in Q1 2022.
• The 5-year median for Total Liabilities is $109.6 million (2024), against an average of $115.0 million.
• Across the five-year window, Total Liabilities surged 413.79% in 2022 and retreated 23.39% in 2025, its largest moves.
• Year by year, Total Liabilities stood at $71.0 million in 2022, then surged by 75.42% to $124.5 million in 2023, then surged by 73.32% to $215.8 million in 2024, then decreased by 0.09% to $215.6 million in 2025, then slipped by 0.51% to $214.5 million in 2026.
• Per Business Quant, the three latest GLUE Total Liabilities figures stand at $214.5 million (Q1 2026), $215.6 million (Q4 2025), and $214.0 million (Q3 2025).